Back to Top Skip to main content

DTRA contributes to historic Ebola vaccine effort

Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz) Air Force Staff Sgt. Lee Nembhard, an aeromedical evacuation technician assigned to the 375th Aeromedical Evacuation Squadron from Scott Air Force Base, Illinois, straps a simulated Ebola patient to a litter during a Transport Isolation System training exercise at Joint Base Charleston, South Carolina. (U.S. Air Force photo by Senior Airman Megan Munoz)

Recommended Content:

Immunization Healthcare | Immunizations | Global Emerging Infections Surveillance | Global Health Engagement | Global Health Engagement

FORT BELVOIR, Va. — The team of researchers and program managers at the Defense Threat Reduction Agency (DTRA) that has worked to counter the threat of the Ebola Virus Disease (EVD) welcomed the announcement of the U.S. Food and Drug Administration’s (FDA) approval of the vaccine, Ervebo ®, to the pharmaceutical company Merck & Co., Inc., December 19, 2019.

The approval of the vaccine represents the culmination of nearly two decades of efforts by a host of teams from across the public and private sectors such as DTRA and Merck, international partners in North America, Europe and Africa, and non-governmental and international organizations. The World Health Organization (WHO) describes EVD as a rare but severe hemorrhagic fever. EVD has killed thousands over the course of outbreaks, primarily in sub-Saharan Africa, since it first appeared in the 1970s.

DTRA, a Department of Defense combat support agency that identifies and combats biological threats as part of its mission to counter weapons of mass destruction (WMD), began its work on the vaccine in 2014 during an especially deadly outbreak in West Africa. The outbreak made clear the danger EVD posed to U.S. national security interests abroad, as well as to the U.S. domestic population in the event of a pandemic. To counter the threat, DTRA quickly initiated a strategy to get a vaccine approved. The combat support agency coordinated a series of investment efforts and partnerships to deliver a baseline platform for a viable vaccine candidate to mitigate the spread of the deadly disease.

“DTRA’s agile contracting, and well-placed contacts throughout government, academia, and industry allowed DTRA to form partnerships and guide development of this vaccine from the early stages of development, through crucial preclinical, and critical phase 1 clinical safety trials to the actual phase 2 clinical efficacy trial that demonstrated effectiveness of this vaccine during the outbreak,” said L. Revell Phillips Ph.D., a member of DTRA’s research and development team.

DTRA’s pioneering approach started with a contract to BioProtection Systems, a small biotech company. DTRA and BioProtection Systems partnered with Public Health Agency Canada, who began developing the vaccine in 2001, to accelerate its development. With these three teams working together, the vaccine progressed to a series of nonclinical and clinical studies conducted at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID) and Walter Reed Army Institute of Research (WRAIR) defense laboratories.

As the effort evolved, DTRA leveraged its USAMRIID partner’s research capacity, resulting in international partnering agreements with the WHO. DTRA also coordinated with teams across the U.S. government as development of the vaccine progressed. The efforts of this research and development consortium produced viable data that would be transitioned to next-level partners.

“We exercised our ability to develop partnerships for a relevant need, which was critical in transitioning medical countermeasures to our advanced developers at the speed of relevancy,” said Army Maj. Jeffrey Froude, DTRA’s program manager for the EVD Vaccine.

Froude explained that DTRA bolstered its research and development investments through two key U.S. governmental partners. First, DTRA worked closely with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, for advanced trials and manufacturing activities. Second, DTRA teamed with the DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for the task of immunoassay development. For that development effort, JPEO-CBRND’s, office of the Joint Program Manager for CBRN Medical took the lead.

Following several years of coordinated research and development efforts by the coalition of partners, the promising vaccine candidate transitioned to next-level partners BARDA and Merck for more advanced human clinical trials and product manufacturing of the EVD vaccine.

“This vaccine’s rapid progress is a testament to the power of partnerships among government agencies and with the private sector,” said BARDA director Rick Bright.

Next-level partner BARDA and Merck, served as the transition point to conduct more advanced human clinical trials and product manufacturing on the Ebola vaccine with the Joint Program Executive office (JPEO) providing a testing capability that allowed Merck to test human and non-human primate samples. The Joint Project Manager for Chemical, Biological, Radiological and Nuclear Medical (JPM-CBRN), Army Col. Ryan Eckmeier, stated that this “interagency partnership from the beginning was critical to advancing this vaccine product.”

Merck’s expertise with licensing and manufacturing was instrumental in advancing the vaccine. The pharmaceutical giant partnered with the WHO, United Nations International Children's Emergency Fund, and Gavi Vaccine Alliance, among others, to strategize on how to best implement future public health preparedness and response efforts against EVD.

“We share in this achievement, and thank you all personally for your amazing support over the last five years,” said Beth-Ann G. Coller, executive director of Merck’s vaccine team in a note to the DTRA team. “This has truly been a journey and one that we are proud to have shared with our colleagues in DoD. Without the early and continued support of DTRA we would not be here today.”

DTRA continues to leverage its successful partnerships as the agency works to develop future countermeasures. DTRA and BARDA have active partnering agreements to develop vaccine and therapeutic medical countermeasures to address a diverse range of viral and bacterial infectious disease threats. Efforts will use a similar model to the one that supported development and approval of the EVD vaccine.

“As DTRA moves forward to new challenges, we will leverage continued utilization of the Ebola vaccine model, using a diverse range of ways that we can work with our academic, international, interagency and industrial partners through grants, contracts and other transaction authorities,” said Froude. “We have a proven paradigm on how to efficiently advance medical countermeasures working with our U.S. government partners in these endeavors.”

Disclaimer: Re-published content may be edited for length and clarity. Read original post.

You also may be interested in...

Coronavirus Disease 2019 (COVID-19) Surveillance Summary #10

Report
3/26/2020

As of 26 MAR, 69,197 confirmed COVID-19 cases (1,046 deaths) have been reported in all U.S. states, the District of Columbia, Puerto Rico, Guam, and the U.S. Virgin Islands.

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries | Coronavirus

DHA IPM 20-002: Southern Hemisphere Influenza Vaccination Program

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), establishes the Defense Health Agency’s (DHA) procedures to implement instructions, assign responsibilities, and prescribe procedures for the Southern Hemisphere Influenza Vaccination Program. All Active Duty, Selected Reserve, and National Guard members receive an annual influenza vaccination. Personnel who are traveling to, conducting a permanent change of station to, or are located in the Southern Hemisphere will receive the Southern Hemisphere influenza vaccine or obtain an exemption (e.g., medical or administrative) in accordance with guidance in paragraph 6.a. of Attachment 2. Military personnel residing in the Southern Hemisphere who have received the Southern Hemisphere influenza vaccine in accordance with Appendix 1, meet the annual influenza immunization requirement.

Coronavirus Disease 2019 (COVID-19) Surveillance Summary #9

Report
3/19/2020

As of 19 MAR, 9,415 confirmed and presumptive positive COVID-19 cases (150 deaths) have been reported in 50 U.S. states and the District of Columbia. States with a high burden of COVID-19 cases include: NY, WA, CA, NJ, FL, IL, and TX. All 50 states and Washington, DC have declared states of emergency.

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries | Coronavirus

Coronavirus Disease 2019 (COVID-19) Surveillance Summary #8

Report
3/12/2020

On 11 MAR, WHO officially characterized COVID-19 as a pandemic, citing “alarming levels of spread and severity, and alarming levels of inaction” as justification for this assessment. The Director-General noted that over the past two weeks, cases reported outside mainland China have increased 13-fold, and the number of affected countries has tripled. From mid-DEC 2019 to 12 MAR 2020, 118,954 cases of COVID-19 (4,295 deaths) have been reported from 121 countries/regions/territories worldwide.

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries | Coronavirus

Immunization Tool Kit 9th Edition

Publication
3/9/2020

A practical reference that facilitates and enhances the global delivery of quality immunization healthcare to Department of Defense (DoD) beneficiaries and employees. The Defense Health Agency Immunization Healthcare Division (DHA-IHD) publishes the Immunization Tool Kit based on national recommendations, evidenced-based, peer-reviewed published medical literature, and clinical practice guidelines.

Recommended Content:

Immunization Healthcare

Coronavirus: What you need to know

Article
3/6/2020
A Guardsmen with the 341st Military Intelligence Battalion conducts translation work on a safety message regarding the best practices for avoiding the novel coronavirus for the Washington Department of Health on Feb. 9, 2020 at the Information Operations Readiness Center, Joint Base Lewis-McChord, Wash. (Courtesy Photo)

Although news stories and images contain many reports of people wearing surgical masks to ward off the virus, that's not recommended

Recommended Content:

Global Health Engagement | Public Health | Coronavirus | Coronavirus

Coronavirus Disease 2019 (COVID-19) Surveillance Summary #7

Report
3/5/2020

From mid-DEC 2019 to 5 MAR 2020, 96,168 cases of COVID-19 (3,269 deaths) have been reported globally, with mainland China accounting for 84% of cases. In recent days, new cases in other countries/regions have exceeded those within mainland China; a cumulative 15,746 cases (253 deaths) have been reported from 18 countries/regions in INDOPACOM, 42 in EUCOM, three in NORTHCOM, 14 in CENTCOM, seven in SOUTHCOM, and six in AFRICOM.

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries | Coronavirus

Coronavirus Disease 2019 (COVID-19) Surveillance Summary #6

Report
2/27/2020

As of 26 FEB, confirmed COVID-19 cases have been reported in at least one country in each U.S. Geographic Combatant Command. From mid-DEC 2019 to 27 FEB 2020, 78,947 cases (2,747 deaths) have been reported in mainland China. Additionally, 4,051 confirmed cases (64 deaths) have been reported in 49 countries and regions outside of mainland China, including USINDOPACOM (15), USAFRICOM (1), USCENTCOM (10), USEUCOM (20), USNORTHCOM (2), and USSOUTHCOM (1).

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries | Coronavirus

Coronavirus Disease 2019 (COVID-19) Surveillance Summary #5

Report
2/20/2020

From mid-DEC 2019 to 20 FEB 2020, 75,778 cases of COVID-19, including 2,120 deaths (case fatality proportion 2.8%), have been reported in mainland China. Additionally, 1,215 confirmed cases (10 deaths) have been reported in 29 countries and regions outside of mainland China, including USINDOPACOM (15), USEUCOM (9), USNORTHCOM (2), and USCENTCOM (3).

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries | Coronavirus

Coronavirus Disease 2019 (COVID-19) Surveillance Summary #4

Report
2/13/2020

From mid-DEC 2019 to 13 FEB 2020, 59,822 confirmed cases of COVID-19, including1,367 deaths (case fatality proportion 2.3%), have been reported in mainland China. On 12 FEB, the Chinese government reported asubstantial increase in cases (+15,074) and deaths (+253). This is due to an expanded case definition (applicable only in Hubei Province) that includes clinically-diagnosed cases in addition to individuals testing positive via PCR. Additionally, 525 confirmed cases have been reported in 27 countries and regions outside of mainland China, including USINDOPACOM (15), USEUCOM (9), USNORTHCOM 2), and USCENTCOM (1).

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries | Coronavirus

Coronavirus Disease 2019 (COVID-19) Surveillance Summary #3

Report
2/10/2020

From mid-DEC to 6 FEB, 28,085 confirmed cases of infection with a novel coronavirus (2019-nCoV), including 565 deaths (case fatality proportion 2.0%) have been reported in mainland China. Additionally, 259 confirmed cases have been reported in 27 countries and regions outside of mainland China, including 15 countries/regions in USINDOPACOM, nine in USEUCOM, two in USNORTHCOM, and one in USCENTCOM.

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries | Coronavirus

MHS prepared to support interagency coronavirus response

Article
2/6/2020
Airmen assist one another in donning their personal protective equipment, while on-board an Air Force C-17 Globemaster III during transportation isolation system training at Joint Base Charleston, South Carolina. Engineered and implemented after the Ebola virus outbreak in 2014, the TIS is an enclosure the Department of Defense can use to safely transport patients with diseases like novel coronavirus. (U.S. Air Force photo by Senior Airman Cody R. Miller)

From R&D to force health protection, MHS protects DoD personnel and families

Recommended Content:

Global Health Engagement | Public Health | Coronavirus | Coronavirus

Coronavirus Disease 2019 (COVID-19) Surveillance Summary #2

Report
2/4/2020

From mid-DEC to 30 JAN, 8,124 cases of infection with a novel coronavirus (2019-nCoV), including171 deaths (case fatality proportion 2.1%) have been reported in mainland China. Additionally, 112 cases have been reported in 21 countries and regions outside of mainland China, including 15 countries/regions in USINDOPACOM, three in USEUCOM, two in USNORTHCOM, and one in USCENTCOM.

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries | Coronavirus

Coronavirus Disease 2019 (COVID-19) Surveillance Summary #1

Report
2/4/2020

From mid-DEC to 24 JAN, Chinese health officials have reported 830 cases of infection (25 deaths, case fatality proportion 3%) with a novel coronavirus (2019-nCoV)in mainland China (29 provinces), with the majority (56%) of cases reported from the city of Wuhan in Hubei Province, the presumed epicenter of the outbreak.

Recommended Content:

Armed Forces Health Surveillance Branch | Global Emerging Infections Surveillance | Integrated Biosurveillance Summaries | Coronavirus

DoD releases guidance to protect forces from novel coronavirus

Article
1/31/2020
The novel coronavirus is a variant of other coronaviruses, such as this colorized transmission electron micrograph of Middle East respiratory syndrome (MERS) virus particles (blue) found near the periphery of an infected VERO E6 cell (yellow). Image captured and color-enhanced at the NIAID Integrated Research Facility in Fort Detrick, Maryland. (Photo by NIAID)

Basic infection controls offer best defense against illness

Recommended Content:

Global Health Engagement | Public Health | Coronavirus | Coronavirus
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 12

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing: Download a PDF Reader or learn more about PDFs.